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Introduction
Prostate cancer (PCa) is the second most frequently diagnosed cancer in men worldwide (Torre et al., 2015) . Currently, few therapeutic options are available for patients with advanced PCa. Tyrosine kinase inhibitors (TKIs), being effective in some human malignancies (Rask-Andersen et al., 2014) , have been used as single agents or in combination with chemotherapy in clinical trials in patients with castration-resistant PCa; however, the results were not promising (Jakobovits, 2008; Gallick et al., 2012; Molife et al., 2014; Ojemuyiwa et al., 2014; Modena et al., 2016) .
Therefore, new mechanism-based inhibitors need to be developed to treat PCa patients. Since neurotransmitters have modulatory effects on tumor cells, the potential roles of receptors for neurotransmitters in tumors have attracted more and more research interests (Schuller, 2008a) .
GABA is a main inhibitory neurotransmitter in the vertebrate central nervous system. Metabotropic GABA B receptor (GABA B R), a G protein-coupled receptor (GPCR) family member, is an obligatory heterodimer composed of GABA B1 and GABA B2 subunits. The extracellular domain of GABA B1 subunit has a ligand binding site for GABA, agonists, or antagonists. Whereas the extracellular domain of GABA B2 subunit lacks the ligand binding capacities, GABA B2 subunit is responsible for G i/o protein coupling. It has been shown that specific allosteric modulators bind to MOL #107854 correlated with the degree of cell differentiation, local invasion, and lymph node metastasis (Huang et al., 2013) . Upregulated expression of GABA B2 subunit is detected in female lung cancer patients with better outcome (Zhang et al., 2013) , while the level of GABA B R has no obvious correlation with the pathological features of human gastric cancer (Zhu et al., 2004) . In vitro studies reveal that GABA B R agonists may inhibit (Fava et al., 2005; Wang et al., 2008; Huang et al., 2013; Zhang et al., 2013; Shu et al., 2016) or dispaly no effect (Abdul et al., 2008; Lodewyks et al., 2011; Zhang et al., 2014) on the proliferation of cancer cells. Activation of GABA B R may promote (Azuma et al., 2003; Inamoto et al., 2007; Zhang et al., 2014) , suppress (Fava et al., 2005; Schuller et al., 2008b; 2008c; Lodewyks et al., 2011) , or have no influences (Joseph et al., 2002; Drell et al., 2003; Chen et al., 2012) on the migration and/or invasion of cancer cells. These observations suggest that the roles of GABA B R in cancer cell proliferation, migration, and tumor malignancy are controversial.
It has been well documented that GPCRs induce the transactivation of various receptor tyrosine kinases (RTKs) including epithelial growth factor receptor (EGFR) family members, insulin-like growth factor receptor 1 (IGF-1R), fibroblast growth factor receptor 1, platelet-derived growth factor receptor, vascular endothelial growth factor receptor 2, TrkA/B, and c-Met (Wetzker and Böhmer, 2003; Tu et al., 2010; Cattaneo et al., 2014; Ryu et al., 2014) . We have reported previously that specific activation of GABA B R induced transactivation of IGF-1R in neurons (Tu et al., 2010;  MOL #107854
Materials and Methods
Antibodies and Reagents
Primary antibodies including pERK1/2 (T202/Y204), ERK1/2, pEGFR (Y845), pEGFR (Y992), pEGFR (Y998), pEGFR (Y1045), pEGFR (Y1068), pEGFR (Y1086), pEGFR (Y1148), pEGFR (Y1173), EGFR, β-actin, EGFR antibody-conjugated sepharose-beads, and horse radish peroxidase (HRP)-conjugated secondary antibodies against mouse and rabbit IgG were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-phosphotyrosine antibody 4G10, 4G10-conjugated agarose-beads, and EGFR neutralizing antibody (LA1) were obtained from Millipore (Billerica, MA, USA).
Pertussis toxin (PTX) and MMPs inhibitor GM6001 (Ilomastat or Galardin) were purchased from Millipore (Billerica, MA, USA). GABA B R agonist baclofen, antagonist CGP54626, PAMs CGP7930, rac-BHFF, and GS39783 were obtained from Tocris Bioscience (Bristol, BS, UK). EGFR inhibitors Tarceva (Erlotinib) and Iressa (Gefitinib) were from Active Biochem (Hongkong, China).
Cell Culture
Human prostate cancer cell line PC-3 was purchased from ATCC. Cells were maintained in F-12 medium (Gibco, China) supplemented with 10% fetal bovine serum (FBS; Gibco, USA), 100 units/ml penicillin, and 100 μg/ml streptomycin (Gibco) at 37°C with 5% CO 2 . Cells were split every 3-4 days and medium was replaced every 2 days.
Treatment of cells with various compounds
1.5×10
5 cells were seeded into 3.5 cm plates and grown in complete medium for 2 days at 37°C with 5% CO 2 . Cells were then serum starved for 24 h followed by incubation with u7 一 serum free medium (SFM) for 30 min before being treated with
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EGFR neutralizing antibody. Cells were incubated with or without 2 μg/ml of EGFR neutralizing antibody at 37°C for 1 h followed by treatment with 200 μM baclofen, 50 μM CGP7930, 100 μM rac-BHFF, or 10 μM GS39783 in the presence or absence of neutralizing antibody at 37°C for 5, 10, 20, and 5 min, respectively.
At the end of each treatment, cells were lyzed with RIPA buffer containing proteinase inhibitors cocktail on ice for 30 min, sonicated for 30 s and centrifuged at 4°C, 13,000 rpm for 10 min to remove cell debris. The supernatants were transferred to new microtubes and stored at -20°C until use or subjected to SDS-PAGE immediately.
Receptor Tyrosine Kinase (RTK) Array Assay
Human RTK array was purchased from RayBiotech (Norcross, GA, USA). The experiment was performed according to manufacturer's instructions. Briefly, PC-3 cells grown in 10 cm plates were serum starved for 24 h followed by treatment with or without 200 μM baclofen at 37°C for 5 min. Cells were then washed quickly with cold PBS, and lyzed immediately with cold RIPA buffer on ice for 30 min. Total cell lysates (TCLs) were sonicated for 30 s and centrifuged at 4°C, 13,000 rpm for 10 min to remove cell debris. Supernatants were diluted by blocking buffer in a final volume of 1.2 ml (300 μg/ml), and incubated with RTK array membranes, which were pre-incubated with blocking buffer overnight at 4°C. The membranes were washed three times (3 min each) with 2 ml of 1×Wash Buffer I at room temperature (RT) with shaking, carefully transferred to a plastic container, and washed with a minimum of 20 ml of 1×Wash Buffer I for three times (5 min each) followed by washing with a minimum of 20 ml of 1×Wash Buffer II for three times (5 min each). The membranes were transferred to an eight-well tray, incubated with 1.2 ml of diluted biotin-conjugated antibody at RT with gentle shaking for 2 h, followed by incubating with 1.5 ml of 1×HRP-conjugated streptavidin for 2 h at RT, washed with 1×Wash MOL #107854
Buffer I and II as described previously. Membranes were developed by using enhanced chemiluminescence reagents (Thermo, China).
Immunoprecipitation
PC-3 cells grown in 10 cm plates were serum starved for 24 h in the presence or absence of PTX (200 ng/ml) followed by treatment with or without 200 μM baclofen at 37°C for 5 min. Serum starved PC-3 cells were also treated with or without 50 μM CGP7930, 100 μM rac-BHFF, or 10 μM GS39783 at 37°C for 10, 20, or 5 min, respectively. At the end of the treatment, cells were washed quickly with cold PBS, and lyzed immediately with cold RIPA buffer on ice for 30 min. TCLs were sonicated for 30 s and centrifuged at 4°C, 13,000 rpm for 10 min to remove cell debris. The supernatants (500 μg) were mixed with 20 μl of 4G10-conjugated agarose-beads or EGFR antibody-conjugated sepharose-beads in a final volume of 500 μl, and incubated at 4°C overnight with continuous agitation. The beads were washed with RIPA buffer for five times (600 μl each) followed by PBS for 2 times, resuspended in 20 μl of 2×electrophoresis loading buffer, boiled for 5 min, and centrifuged at 12,000 rpm for 5 min. The supernatants were transferred to new microtubes and subjected to immunoblot analysis.
Immunoblot Analysis
Equal amounts of TCLs were resolved by 10% SDS-PAGE gels followed by membrane transfer. Membranes were blocked with TBS containing 5% non-fat dry milk and 0.1% Tween-20 for 2 h at RT, and incubated with primary antibodies against EGFR, pEGFR (Y845), pEGFR (Y992), pEGFR (Y998), pEGFR (Y1045), pEGFR antibodies (1:20,000-1:30,000) at RT for 2 h. Membranes were then washed and developed by using enhanced chemiluminescence reagents.
Enzyme Linked-Immunosorbent Assay (ELISA)
Human EGF, heparin-binging EGF (HB-EGF), amphiregulin (AR), and transforming growth factor-α (TGF-α) ELISA kits were purchased from BOSTER (Pleasanton, CA 94566, USA). Serum starved PC-3 cells seeded on 3.5 cm plates were treated with 200 μM baclofen at 37°C for 0, 5, 10, or 15 min, and conditioned media (CM) were transferred to 1.5 ml microtubes. 100 μl CM or standards were added into 96-well plates and incubated at 37°C for 90 min followed by extensive washing. 100 μl biotinylated antibodies were then added to the plates, incubated at 37°C for 60 min followed by 3 washes (1 min each). 100 μl avidin-biotin-peroxidase complex working solution was added to the plates except the tetramethylbenzidine (TMB) blank well and incubated at 37°C for 30 min followed by five washes (1-2 min each 
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Results
GABA B R agonist induced EGFR transactivation in human PCa cells
The expression of GABA B R was detected in human PCa cell lines PC-3 and LNCaP (Fig. S1) . To identify whether activation of GABA B R hijacks RTKs signaling to modulate the fates of PCa cells, RTK array analysis was performed in PC-3 and LNCaP cells, which were stimulated with a specific GABA B R agonist, baclofen ( Fig.   S2A ), for 5 min. The results showed that baclofen selectively upregulated the phosphorylation level of EGFR but not other RTKs in PC-3 cells (Fig. 1A) .
To confirm the results of RTK array assay, PC-3 cell lysates prepared from untreated 
3G).
To identify which EGFR pro-ligand(s) was/were released by MMPs from cell surface, ELISA experiments were performed. As shown in Fig. 3H , the basal EGF level in control group was 3.177±0.292 pg/ml (n=3), baclofen treatment for 5, 10, or 15 min increased EGF level to 4.008±0.214 pg/ml (p<0.05, n=3), 4.888±0.361 pg/ml (p<0.05, n=3) and 6.056±0.235 pg/ml (p<0.05, n=3) respectively. Baclofen had no significant influence on HB-EGF level until fifteen-minute-treatment, while no upregulation of TGF-α and AR levels was detected in the presence of baclofen (Data not shown). These data indicated that production of EGF but not HB-EGF was upstream of ERK1/2 phosphorylation upon GABA B R activation, therefore, MMPs-mediated shedding of pro-EGF might be involved in baclofen induced EGFR signaling in PC-3 cells.
GABA B R agonist promoted migration and invasion of PC-3 cells
Baclofen has been shown to enhance the invasive ability of human prostate C4-2 cancer cells (Azuma et al., 2003) . To analyze the effects of baclofen on migration and As a control, Baclofen displayed no effect on the survival of PC-3 cells after 96 h treatment. However, CGP54626 inhibited cell survival in a time-and dose-dependent manner, and 40 μM CGP54626 significantly inhibited cell survival after 48 h treatment (Fig. S4) .
PAMs of GABA B R directly induced ERK1/2 activation as PAM agonists
CGP7930, rac-BHFF, and GS39783, the PAMs of GABA B R (Fig. S2C) , are capable of modulating the efficacy of GABA B R induced signal transduction (Urwyler et al., 2001; 2003; 2005; Malherbe et al., 2008) . PAM agonist activities of these three compounds have been reported previously (Binet et al., 2004; Tu et al., 2007; 2010; Malherbe et al., 2008; Gjoni and Urwyler, 2009; Koek et al., 2010; Gannon and Millan, 2011; Sun et al., 2016 phosphorylation induced by rac-BHFF was similar to that induced by CGP7930, which was sustained, peaking at 20 min, and lasting for more than 2 h. The minimum concentration of rac-BHFF to activate ERK1/2 was 75 μM (Figs. 6D and 6E ).
ERK1/2 activation induced GS39783 was similar to that induced by baclofen, which was transient, peaked at 5 min, and returned to basal level after 30 min. 0.6 μM of GS39783 was sufficient to induce ERK1/2 phosphorylation, and 5 μM GS39783 resulted in maximum phosphorylation of ERK1/2 with an EC50 value of 4.85 μM
(Figs. 6G and 6H).
It has been documented that PC-3 cells may synthesize endogenous GABA (Ippolito and Piwnica-Worms, 2014). To clarify whether ERK1/2 activation induced by PAMs was due to a direct agonistic effect or the potentiation of endogenously produced GABA, PC-3 cells were pre-treated with GABA B R antagonist CGP54626 followed by PAMs. The results showed that CGP54626 did not abrogate ERK1/2 activation induced by CGP7930 and rac-BHFF (Figs. 6C and 6F) , suggesting that CGP7930 and rac-BHFF had a direct agonistic effect on ERK1/2 activation. GS39783 induced activation of ERK1/2 was suppressed by CGP54626 (Fig. 6I) , indicating that GS39783 may function as a pure PAM in PC-3 cells.
PAMs of GABA B R stimulated EGFR signaling in PC-3 cells
To investigate whether CGP7930, rac-BHFF, and GS39783 can activate EGFR signaling in PC-3 cells, immunoprecipitation experiments were performed. The results
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showed that these three PAMs significantly increased the total phosphorylation level of EGFR (Figs. 7A-7C ). Further analysis showed that ERK1/2 phosphorylation induced by CGP7930, rac-BHFF, and GS39783 was suppressed by EGFR inhibitors Tarceva (Figs. 7D-7F) , Iressa (Figs. 7G-7H) , and EGFR neutralizing antibody (Figs.
7J-7L).
These results suggested PAMs of GABA B R functioned similarly as baclofen to induce EGFR transactivation and EGFR ligand-dependent ERK1/2 activation.
CGP7930 promoted migration and invasion of PC-3 cells
Based on the time and dose effects of CGP7930 on cell survival (data not shown), transwell experiments were performed in the presence of maximal 4 μM CGP7930.
As shown in 
MOL #107854
Discussion
EGFR family has received much attention in pharmacological research due to their strong association with malignant proliferation (Gallick et al., 2012) . In addition to direct activation by specific ligands, EGFR family members could also be transactivated by a variety of GPCR agonists (Daub et al., 1996; Zhou et al., 2012; Cattaneo et al., 2014; Muñoz-Moreno et al., 2014; Lai et al., 2016; Wang, 2016) . In 10 min later than that of pro-EGF. Therefore, EGF might be the main ligand that induces the fast transactivation of EGFR. AR and TGF-α was not detected in this study, probably due to lack of expression or shedding of these two ligands, or the concentration of these two ligands were too low to be detected.
We have reported previously that GABA B R induced transactivation of IGF-1R in neurons in a ligand-independent pathway, which was mediated by phospholipase C, But we didn't exclude the possibility that GS39783 may have a direct agonist activity.
As described in Materials and Methods, serum starved PC-3 cells were washed with SFM before PAMs treatment, so the endogenous level of GABA in PC-3 cells might be too low to be effective. The different effects of CGP54626 on ERK1/2 activation induced by CGP7930, rac-BHFF, and GS39783 suggested that GABA B R PAMs may have distinct binding sites on the transmembrane domain of GABA B2 subunit. Upon CGP54626 binding, both GABA B1 and GABA B2 subunits undergo a conformational change, which may distort the binding site for GS39783 but retain the binding capacity for CGP7930 and rac-BHFF.
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It has been reported that GABA simulated proliferation of PC-3 cells (Wu et al., 2014) .
In this study, baclofen displayed no effect on the survival of PC-3 cells, but GABA B R antagonist CGP54626 inhibited cell survival. Therefore, the effect of baclofen on the survival of PC-3 cells was probably masked by endogenous GABA; when the effect of GABA was blocked by GABA B R antagonist, cell survival was suppressed.
This study showed that both baclofen and CGP7930 significantly promoted migration 
